FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women with BRCA1 mutations who have had risk-reducing ovary removal and have never been diagnosed with breast cancer
Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this study, researchers showed that among women with BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Gardening improves health outcomes for breast cancer patients
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People diagnosed with breast cancer who would benefit from increased activity and from eating more vegetables
Research has shown that adopting a healthier lifestyle may improve overall health and outcomes for cancer survivors. This study looked at a 1-year home-based gardening intervention to increase activity and wellbeing among breast cancer survivors. (08/31/18)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Study identifies genes associated with risk of triple-negative breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People diagnosed with triple-negative breast cancer
Panel testing can identify women who are at increased risk for breast cancer. However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown. A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)
Read MoreStudy : Declining use of chemotherapy for early-stage breast cancer: examining oncologist recommendations
Most relevant for: People diagnosed with early stage breast cancer
A new study shows that chemotherapy use for early-stage, node-positive and node-negative breast cancers declined from 2013 to 2015. It also reports that oncologists’ recommendations are influenced to differing degrees by patient preferences and tumor test results, despite unchanging health care guidelines. (8/21/18)
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Immunotherapy may lead to long-term remission of metastatic breast cancer
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with advanced cancers
Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)
Read MoreArticle : Interview with Angelina Jolie's doctor promotes meatless diet and scientific inaccuracies
Most relevant for:
Dr. Kristi Funk, Angelina Jolie's Hollywood breast surgeon, is promoting her new book about breast cancer. This article from the UK newspaper The Times includes an interview with Funk about her book, which proposes that diet is responsible for breast cancer. This XRAYS addresses scientific inaccuracies in this article. (8/7/18)
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Some women with early-stage breast cancer forego chemotherapy
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with node-negative, ER-positive breast cancer
A research study named the “Trial Assigning Individualized Options for Treatment” (TAILORx) asked whether chemotherapy is beneficial for women who have mid-range Oncotype DX tumor recurrence scores. This trial — the largest breast cancer treatment trial ever conducted— showed that endocrine therapy alone was as effective as endocrine therapy plus chemotherapy in women with certain types of early-stage breast cancer. The results of this trial are expected to be immediately practice changing (7/20/18)
Read MoreArticle : High health insurance deductibles can interfere with breast cancer treatment decisions
Most relevant for: People diagnosed with breast cancer
A New York Times article published on May 4, 2018 examines the impact of high insurance deductibles on breast cancer treatment. (7/12/18)
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People who are considering or have had direct-to-consumer testing
A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Disparities in research impact breast screening guidelines
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women at average risk for breast cancer
For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences. A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)
Read More